OUR PIPELINE

We believe that our potential therapies will have the ability to transform the lives of people with a wide spectrum of diseases, including many types of cancer. Through our pipeline of proprietary enzymatic inhibitors, targeted protein degraders, and transcription factor disruptors, we are building the next wave of precision therapies.

Program/Target Indication Disease Discovery Phase 1 Phase 2 Phase 3 Global Rights
FHD-286
(SMARCA2 AND SMARCA4)
AML Combination Study Relapsed/Refractory AML
Foghorn Therapeutics
FHD-909 (Selective SMARCA2)
SMARCA4 Mutated Cancers SMARCA4 mutant cancers (e.g., ~8-10% of NSCLC, bladder, endometrial, colorectal)
Foghorn Therapeutics and Loxo Oncology at Lilly
Partnered Program (Undisclosed)
Undisclosed Undisclosed
Foghorn Therapeutics and Loxo Oncology at Lilly
Selective SMARCA2
SMARCA4 Mutated Cancers SMARCA4 mutant cancers (e.g., ~8-10% of NSCLC, bladder, endometrial, colorectal)
Foghorn Therapeutics and Loxo Oncology at Lilly
Selective CBP
EP300 Mutated Cancers EP300 mutant cancers (e.g., ~5-10% of bladder, gastric, breast, NSCLC, colorectal)
Foghorn Therapeutics
Selective EP300
CBP Mutated & Subsets of EP300 Dependent Cancers EP300 dependent cancers (e.g., prostate, DLBCL),
CBP mutant cancers (e.g., ~9-10% of NSCLC, bladder, melanoma)
Foghorn Therapeutics
Selective ARID1B
ARID1A Mutated Cancers ARID1A mutant cancers (~5% of all solid tumors)
Foghorn Therapeutics
Undisclosed
Undisclosed Undisclosed
Foghorn Therapeutics
3 Discovery Programs (Undisclosed)
Undisclosed Undisclosed
Foghorn Therapeutics and Loxo Oncology at Lilly
Additional Discovery  

Using our proprietary Gene Traffic Control® platform, we have identified additional genetically determined dependencies to drug using enzymatic inhibitors, protein degraders and transcription factor disruptors

  

While initially focused on the BAF chromatin regulatory complex, we believe our platform is broadly applicable to other chromatin remodeling complexes, other transcription factors, and other diseases.

  • Enzyme Inhibitors
  • Protein Degraders
  • Transcription Factor Disruptors
  • Undisclosed
  • Enzyme Inhibitors
  • Protein Degraders
  • Transcription Factor Disruptors
  • Undisclosed
FHD-286
(SMARCA2 AND SMARCA4)
Relapsed/Refractory AML
Global Rights: Foghorn Therapeutics

AML Combination Study

Phase 1
FHD-909 (Selective SMARCA2)
SMARCA4 mutant cancers (e.g., ~8-10% of NSCLC, bladder, endometrial, colorectal)
Global Rights: Foghorn Therapeutics

SMARCA4 Mutated Cancers

Phase 1
Partnered Program (Undisclosed)
Undisclosed
Global Rights: Foghorn Therapeutics

Undisclosed

Discovery
Selective SMARCA2
SMARCA4 mutant cancers (e.g., ~8-10% of NSCLC, bladder, endometrial, colorectal)
Global Rights: Foghorn Therapeutics

SMARCA4 Mutated Cancers

Discovery
Selective CBP
EP300 mutant cancers (e.g., ~5-10% of bladder, gastric, breast, NSCLC, colorectal)
Global Rights: Foghorn Therapeutics

EP300 Mutated Cancers

Discovery
Selective EP300
EP300 dependent cancers (e.g., prostate, DLBCL),
CBP mutant cancers (e.g., ~9-10% of NSCLC, bladder, melanoma)
Global Rights: Foghorn Therapeutics

CBP Mutated & Subsets of EP300 Dependent Cancers

Discovery
Selective ARID1B
ARID1A mutant cancers (~5% of all solid tumors)
Global Rights: Foghorn Therapeutics

ARID1A Mutated Cancers

Discovery
Undisclosed
Undisclosed
Global Rights: Foghorn Therapeutics

Undisclosed

Discovery
3 Discovery Programs (Undisclosed)
Undisclosed
Global Rights: Foghorn Therapeutics

Undisclosed

Discovery
Additional Discovery

Using our proprietary Gene Traffic Control® platform, we have identified additional genetically determined dependencies to drug using enzymatic inhibitors, protein degraders and transcription factor disruptors

While initially focused on the BAF chromatin regulatory complex, we believe our platform is broadly applicable to other chromatin remodeling complexes, other transcription factors, and other diseases.

OUR CANDIDATES IN THE CLINIC

FHD-286

FHD-286 is an enzymatic inhibitor of SMARCA 2 (BRM) and SMARCA4 (BRG1), which are two highly similar proteins that are the ATPases, or catalytic engines, across all forms of the BAF complex. Every BAF complex includes either SMARCA2 or SMARCA4. FHD-286 inhibits the function of SMARCA2 and SMARCA4 in cancers that are heavily dependent on SMARCA2 and SMARCA4.

Target & Modality

SMARCA2/SMARCA4 ATPase

Highly potent, selective, allosteric, small molecule, oral enzymatic inhibitor

Initial Indication

Acute myeloid leukemia (AML)

Genetic Dependency

AML: Elevated SMARCA4 -BAF / TF activity in AML blast cells

FHD-909

FHD-909 (LY4050784) is a potent, first-in-class, allosteric and orally available small molecule that selectively inhibits the ATPase activity of SMARCA2 (BRM) over its closely related paralog SMARCA4 (BRG1), two proteins that are the catalytic engines across all forms of the BAF complex, one of the key regulators of the chromatin regulatory system. In preclinical studies, tumors with mutations in SMARCA4 rely on SMARCA2 for BAF function. FHD-909 has shown significant anti-tumor activity across multiple SMARCA4 mutant lung tumor models.

Target & Modality

SMARCA2 ATPase

Potent, selective, allosteric, small molecule, oral enzymatic inhibitor

Primary Indication

Non-Small Cell Lung Cancer

Genetic Dependency

SMARCA4-mutated cancers

Preclinical & Discovery Programs

We have used our Gene Traffic Control® platform to discover other programs currently in the early preclinical stage, including:

  • A selective SMARCA2 degrader program, which targets cancers with mutations in the SMARCA4 subunit of the BAF complex.
  • A Selective CBP degrader program, targeting EP300 mutated cancers, e.g., subsets of bladder, colorectal, breast, gastric and lung cancers
  • A Selective EP300 degrader program, targeting EP300 dependent cancers and CBP mutant cancers, e.g. prostate cancer, diffuse large B-cell lymphoma (DLBCL), bladder and melanoma.
  • An ARID1B degrader program, with the goal of targeting cancers with mutations in the ARID1A subunit of the BAF complex.
  • Compounds that disrupt the interactions between transcription factors and chromatin remodeling complexes.

OUR COLLABORATOR

Our collaboration with Lilly includes a co-development and co-commercialization agreement on the selective SMARCA2 oncology program (a selective inhibitor and a selective degrader) and an additional undisclosed oncology target. The partnership also includes three additional discovery programs using Foghorn’s proprietary Gene Traffic Control® platform.

Investor Resources

View investor portal

Find out more about our company, accomplishments, news, and latest events.